MRC People Exchange Programme

The MRC People Exchange Programme aims to stimulate collaborative research across industry and academia, develop skills and transfer knowledge. It is one of several new schemes designed with MRC’s industry partners to deliver identifiable translational research outcomes and build long term industry-academic partnerships.

MRC Technology enters into an exclusive license agreement with Genentech

Genentech, Inc.has entered into an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease. This is the first small molecule chemistry programme to come out of MRC Technology’s Centre for Therapeutics Discovery (CTD) and the first major small molecule collaboration the CTD has formed with an industry partner.

“Skills Swap” to exploit expertise for patient benefit

Cancer Research Technology (CRT) and MRCT will ‘swap’ medical discoveries to accelerate the translation of early scientific research into patient benefit. CRT and MRCT can offer each other rights to manage, develop and license discoveries from research funded by parent charity Cancer Research UK and the government’s Medical Research Council. The arrangement will explore ways to make the most of each organisation’s expertise and speed up the licensing of potential products for patient benefit.

AstraZeneca and MRC Technology form strategic alliance in discovery research, utilising shared compound libraries

The companies will combine up to 100,000 compounds from AstraZeneca’s collection with the MRC Technology compound library of approximately 50,000 compounds. MRC Technology will screen this larger combined library searching for compounds that show activity against novel biological targets. A joint steering committee will review these hits, and decide how to advance promising compounds that could become innovative medicines.

Justin Bryans talks to Chemistry World

Justin talks about diseases of poverty, developing new therapeutics and treatments for Parkinson's disease. Visit the Chemistry…

Adding value to early stage IP

Mike Dalrymple, Director at MRC Technology, has written an article for The Innovation Handbook about adding value…

O2h provides multi-FTE -synthetic chemistry services to MRCT

MRCT translates cutting edge scientific discoveries into commercial products, two of which (Tysabri and Actemra) are already on the market. The MRCT Centre for Therapeutics Discovery works closely with the MRCT Intellectual Property and Business Development Division and is rigorous in the selection of well‐defined and characterised targets, and considers novelty, validation and ‘druggability’. In addition, the group works on targets where there is a clear strategy for progression and development.

MRCT’s call for targets

A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today. The MRCT Centre for Therapeutics Discovery (CTD), based in London, is seeking small molecule drug discovery and therapeutic antibody targets from academic researchers.

Collaboration between Georg-August-University Göttingen, Universitätsmedizin, the University of Regensburg and MRCT

The collaboration will focus on development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and multiple sclerosis (MS).